Your search results

Automated CLIA assay for the quantitative determination of alpha-fetoprotein (AFP) in human serum as well as in EDTA and heparinized human plasma or amniotic fluid. The test can be used as an aid for pregnancy monitoring and as an aid during the follow-up of tumor patients.

Automated CLIA assay for the quantitative determination of β2-microglobulin (B2M) in human serum, plasma and urine. This test can be used as an aid in the diagnosis of active rheumatoid arthritis and kidney disease. The test can be used as an aid in the evaluation of the severity and prognosis of certain cancers including multiple myeloma and some lymphomas.

Automated CLIA assay for the quantitative determination of CA 125 antigen in human serum as well as in EDTA or heparinized human plasma. The test can be used as an aid during the follow-up of patients with primary invasive ovarian carcinoma.

Automated CLIA assay for the quantitative determination of the CA 15-3^® antigen in human serum as well as EDTA and heparinized plasma. The test can be used as an aid during the follow-up of patients with breast carcinoma.

Automated CLIA assay for the quantitative determination of the CA 19-9^™ antigen in human serum as well as EDTA or citrated human plasma. The test can be used as an aid during the follow-up of patients with gastrointestinal tumors.

Automated CLIA assay for the quantitative determination of calcitonin in human serum. The determination of calcitonin is an aid in the diagnosis of calcitonin disorders and in the management of medullary thyroid carcinoma.

Automated CLIA assay for the quantitative determination of carcinoembryonic antigen (CEA) in human serum as well as in EDTA or heparinized human plasma. The test can be used as an aid during the follow-up of cancer patients. 

Automated CLIA assay for the quantitative determination of free human prostate-specific antigen (fPSA) in human serum and plasma (EDTA or heparinized). The combined use of free PSA and total PSA is an aid in the discrimination of benign and malignant disease with increased specificity of early detection of prostate cancer.

Automated CLIA assay for the quantitative determination of neuron-specific enolase (NSE) in human serum and CSF. The test can be used as an aid for the management of patients with suspected or diagnosed neuroblastoma or small cell lung carcinoma.

Automated CLIA assay for the quantitative determination of human prostate-specific antigen (PSA) in human serum and plasma (heparinized, EDTA). The combined use of free PSA and total PSA is an aid in the discrimination of benign and malignant disease with increased specificity of early detection of prostate cancer.

Automated CLIA assay for the determination of protein S-100B in human serum and CSF (cerebrospinal fluid). The test can be used as an aid in the diagnosis of malignant melanoma and as an aid of diagnosis and prognosis of traumatic brain injury.

Automated CLIA assay for the quantitative determination of Thymidine Kinase (TK) activity in human serum or EDTA plasma. Determination of serum Thymidine Kinase activity is useful for prognosis and monitoring of patients with hematological malignancies. Assay results should be used in conjunction with other clinical and laboratory data to assist in the diagnosis and management of conditions involving hematologic malignancies.

Automated CLIA assay for the quantitative determination of tissue polypeptide antigen, TPA^®, in human serum. This test can be used an aid in the diagnosis of patients with carcinomas such as lung cancer, breast cancer, bladder cancer and therapy monitoring after tumor surgery or treatment.